HomeEXECUTIVESRandy Pritchard Appointed CEO of Pillar Biosciences

Randy Pritchard Appointed CEO of Pillar Biosciences

Randy Pritchard has been appointed as Chief Executive Officer. The company’s founder, industry veteran and renowned scientific innovator, Gang Song, Ph.D., will transition to the role of Chairman of the Board, where he will be responsible for leading the Board, ensuring governance standard and focusing on all strategic matters for Pillar Biosciences.

In his new role as CEO, Randy Pritchard will look to accelerate the company’s efforts to make precision oncology accessible for all patients throughout the patient journey.

Mr. Pritchard brings to Pillar Biosciences more than 24 years of healthcare experience, as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics.

“On behalf of the Board, I am excited to welcome Randy to lead Pillar Biosciences in its next stage of growth. He brings invaluable experience, as we accelerate our growth with the launch of our oncoReveal™ Dx Lung and Colon Cancer Assay, which received FDA Premarket Approval recently,” said Gang Song, Ph.D., Co-Founder and Chairman of the Board, Pillar Biosciences. “Pillar Biosciences was founded with a mission to make precision medicine accessible for all, by simplifying clinical next-generation sequencing (NGS) and bringing testing closer to the patient.”

“The Board was impressed by Randy’s depth of understanding of the diagnostics space and what drives growth, as well as his leadership experience,” said Simone Song, Founder, ORI Capital who has led repeated investments in Pillar Biosciences since its Series A financing. “His ability to quickly analyze a business, develop and execute on the growth strategy was truly remarkable. I am fully confident that Randy will be an outstanding leader for Pillar at this next stage of growth.”

“I look forward to working with Gang and the Pillar Biosciences team to accelerate the adoption of oncoReveal™ Dx and bring more innovative NGS cancer testing products to patients, in particular in the area of liquid biopsy,” said Randy Pritchard, CEO, Pillar Biosciences. “Pillar has grown to over 150 dedicated team members in the US and China, and I look forward to leading the company in its next stage of growth to become a global clinical cancer NGS diagnostics company.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy